HealthQuill Articles by: HealthQuill
The US Food and Drug Administration (FDA) has granted an accelerated approval for AbbVie Inc.’s drug to treat a specific group of adult lung cancer patients who have tried other systemic treatments.
Drugs Health Pharma

AbbVie’s NSCLC lung cancer drug gets accelerated approval from FDA

 HQ Team May 15, 2025: The US Food and Drug Administration (FDA) has granted an accelerated approval for AbbVie Inc.’s drug to treat

Read More
Harvard University has amended its lawsuit against the US administration by saying that its researchers would lose another $450 million in grants from several agencies.
Health Medical Pharma

Harvard amends lawsuit as federal agencies threaten to cut short grants

HQ Team May 15, 2025: Harvard University has amended its lawsuit against the US administration by saying that its researchers would lose another

Read More
Merck & Co. got approval from the US Food and Drug Administration for a pill to treat a rare type of tumour in adults and children aged above 12 years, according to a statement.
Drugs Health Pharma

Merck’s pill to treat rare type of tumour gets approval from US regulator

HQ Team May 15, 2025: Merck & Co. got approval from the US Food and Drug Administration for a pill to treat a

Read More
Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor that may cure chronic pain without using opioids.
Drugs Health Pharma

Novo Nordisk, Septerna in $2.2b deal to develop oral molecules

HQ Team May 14, 2025: Novo Nordisk and Septerna, Inc., have inked a $2.2 billion global collaboration and licensing pact to develop oral

Read More
GSK Plc will acquire Boston Pharmaceutical’s investigational lead asset, efimosfermin alfa, to treat serious liver diseases, for $2 billion in cash.
Drugs Health Pharma

GSK to buy Boston’s lead drug asset for liver disease for $2 billion in cash

HQ Team May 14, 2025: GSK Plc will acquire Boston Pharmaceutical’s investigational lead asset, efimosfermin alfa, to treat serious liver diseases, for $2

Read More
Mice treated with a special protein called Klotho for a year showed marked improvements in longevity and physical health, opening up potential therapies for humans.
Drugs Health Research

Spanish researchers redesign protein to improve lifespan, brain power in mice

HQ Team May 14, 2025: Mice treated with a special protein called Klotho for a year showed marked improvements in longevity and physical

Read More
UN relief chief Tom Fletcher has told the Security Council that the ambassadors must finally act decisively "to prevent genocide" and ensure respect for international law in Gaza, where it has been 10 weeks since humanitarian aid has been delivered.
Drugs Health Medical

Security Council must act to prevent ‘genocide’ in Gaza: UN relief chief says

HQ Team May 14, 2025: UN relief chief Tom Fletcher has told the Security Council that the ambassadors must finally act decisively “to

Read More
Bonobos, often called pygmy chimpanzees, use the human equivalent of word compounds and phrasings, allowing Harvard researchers to assemble a “dictionary” on animal communication.
Health Medical Research

Bonobo talk bears a striking similarity to human speech: Harvard researchers

HQ Team May 13, 2025: Bonobos, often called pygmy chimpanzees, use the human equivalent of word compounds and phrasings, allowing Harvard researchers to

Read More
Antibiotic use in girls in the first year of life, especially in the first three months, may be linked to the earlier onset of puberty, a study by South Korean researchers finds.
Drugs Health Research

Antibiotic use in girls may trigger early onset of puberty: Study

 HQ Team May 13, 2025: Antibiotic use in girls in the first year of life, especially in the first three months, may be

Read More
Anixa Biosciences, Inc., announced that its partner Cleveland Clinic has begun enrolling subjects in a treatment arm to evaluate the combination of the company's breast cancer vaccine with Merck’s Keytruda (pembrolizumab) immunotherapy.
Drugs Research

AstraZeneca’s blood cancer combination drug shows positive results in end trial

HQ Team May 13, 2025: AstraZeneca’s POTOMAC Phase III trial has demonstrated that combining Imfinzi (durvalumab) with standard Bacillus Calmette-Guérin (BCG) therapy significantly improves disease-free survival (DFS) in patients

Read More